Intra-individual Reproducibility in Nerve Block Duration

NCT ID: NCT03310047

Last Updated: 2018-05-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-30

Study Completion Date

2018-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An interventional randomized controlled crossover trial, to illuminate if durations in nerve block durations are predictable within the same subject.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An interventional randomized controlled crossover trial, with the purpose to elucidate the reproducibility in nerve block duration on 20 healthy volunteers in Denmark.

There will be two trial arms:

1: Day one; Right side low dose nerve block and left side high dose nerve block. Repeated after 24 hours. Day three; Left side low dose nerve block and right side high dose nerve block. Repeated after 24 hours

2: Day one; Left side low dose nerve block and right side high dose nerve block Repeated after 24 hours Day three; Right side low dose nerve block and left side high dose nerve block Repeated after 24 hours

All volunteers will receive two peripheral nerve blocking catheters adjacent to the common peroneal nerve and will be treated two times on each side with Lidocaine 0.5% 5 mL and 10 mL.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia, Regional

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

We will use a two-armed crossover design.

1. Day one; Right side low dose nerve block and left side high dose nerve block

* Repeated after 24 hours Day three; Left side low dose nerve block and right side high dose nerve block
* Repeated after 24 hours
2. Day one; Left side low dose nerve block and right side high dose nerve block

* Repeated after 24 hours Day three; Right side low dose nerve block and left side high dose nerve block
* Repeated after 24 hours
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
The process of intervention-implementation and intervention will not be in the participant's line of sight.

Investigators will not be in the room during the intervention. Outcome assessors will not be in the room during the intervention.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Right-low, left-high

The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 5 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 10 mL.

This will be repeated after 24 hours.

Group Type EXPERIMENTAL

Infusion, Lidocaine, 0.5%, 5 mL

Intervention Type DRUG

A catheter-based perineural infusion of 5 mL Lidocaine 0.5%

Infusion, Lidocaine, 0.5%, 10 mL

Intervention Type DRUG

A catheter-based perineural infusion of 10 mL Lidocaine 0.5%

Right-high, left-low

The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 10 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 5 mL.

This will be repeated after 24 hours.

Group Type EXPERIMENTAL

Infusion, Lidocaine, 0.5%, 5 mL

Intervention Type DRUG

A catheter-based perineural infusion of 5 mL Lidocaine 0.5%

Infusion, Lidocaine, 0.5%, 10 mL

Intervention Type DRUG

A catheter-based perineural infusion of 10 mL Lidocaine 0.5%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Infusion, Lidocaine, 0.5%, 5 mL

A catheter-based perineural infusion of 5 mL Lidocaine 0.5%

Intervention Type DRUG

Infusion, Lidocaine, 0.5%, 10 mL

A catheter-based perineural infusion of 10 mL Lidocaine 0.5%

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Low dose High dose

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 years
2. ASA classification ≤ II

Exclusion Criteria

1. Allergy to local anaesthetics
2. Body weight 40 kg
3. Possible peripheral nerve injury or disease, including polyneuropathy and diabetes
4. Enrolment or recent participation in studies that may interfere with this study
5. Habitual use of any kind of analgesic medications
6. Anatomic abnormalities preventing successful US-guided Certa Catheter™ insertion.
7. Pregnancy or breastfeeding
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Innovation Fund Denmark

INDIV

Sponsor Role collaborator

Nordsjaellands Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mikkel Herold Madsen

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kai L Lange, MD, DMSci

Role: STUDY_DIRECTOR

Nordsjaellands Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Unit, Department of Anaesthesiology, Nordsjaellands Hospital Hilleroed

Hillerød, Capital Region of Denmark, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Re_Injection

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.